The treatment for breast cancer is often seen as worse than the disease. For both its costs and side-effects. OncoStem’s Cancer Recurrence Possibility Test could indicate if the tumor is likely to recur or not. This could make chemotheraphy avoidable for many patients.
The cost of the test was steep which made the doctors hesitant to recommend it to patients who might ascribe an ulterior motive to their recommendation.
We shifted the onus of starting the conversation from the doctor to the patient and their loved ones. Once a patient or their care-giver initiated the conversation, the doctors could freely counsel them about the merits of taking the test.